The Safety and Efficacy of Naltrexone and Scopolamine Utilized in the Treatment of Major Depression

• Status: Completed
• Trial end date: 2018-11-20
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this clinical trial is to determine the safety and efficacy of scopolamine utilized in conjunction with naltrexone for the treatment of major depression.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: The Taub Group
• Treatments: Butylscopolammonium Bromide; Naltrexone; Scopolamine

Criteria

Inclusion Criteria:

• male or female, aged 18-65

• in good health other than major depression for 8 weeks or more

• negative pregnancy test

• able to comply with instructions

• able to provide informed consent

Exclusion Criteria:

• pregnant or lactating

• danger to self or others

• severe kidney or liver disease

• schizophrenia

• allergy to scopolamine or naltrexone

• glaucoma

• Monoamine oxidase (MAO) inhibitor use